Cadralazine | CAS#64241-34-5 | peripheral arteriolar vasodilator

MedKoo Cat#: 561621 | Name: Cadralazine

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cadralazine is a peripheral arteriolar vasodilator and an antihypertensive drug.

Chemical Structure

Cadralazine

CAS#64241-34-5

Theoretical Analysis

MedKoo Cat#: 561621

Name: Cadralazine

CAS#: 64241-34-5

Chemical Formula: C12H21N5O3

Exact Mass: 283.1644

Molecular Weight: 283.33

Elemental Analysis: C, 50.87; H, 7.47; N, 24.72; O, 16.94

Price and Availability

Size	Price	Availability	Quantity
100mg	USD 450.00	2 Weeks
250mg	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Cadralazine; ISF-2469; ISF 2469; ISF2469;

IUPAC/Chemical Name

Ethyl N-[[6-[ethyl(2-hydroxypropyl)amino]pyridazin-3-yl]amino]carbamate

InChi Key

QLTVVOATEHFXLT-UHFFFAOYSA-N

InChi Code

InChI=1S/C12H21N5O3/c1-4-17(8-9(3)18)11-7-6-10(13-15-11)14-16-12(19)20-5-2/h6-7,9,18H,4-5,8H2,1-3H3,(H,13,14)(H,16,19)

SMILES Code

O=C(OCC)NNC1=NN=C(N(CC)CC(O)C)C=C1

Appearance

Solid powder

Purity

>95% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

In vitro activity:

In vivo activity:

30 min after intravenous (i.v.) injection of cadralazine in a dose of 1 mg/kg diastolic blood pressure (DBP) decreased from the control value of 115 +/- 4 mmHg to 108 +/- 3 mmHg. The decrease continued, being accompanied by an increase in heart rate, throughout the experimental period of 5 h. Renal vascular resistance was decreased significantly, while glomerular filtration rate and urine volume remained unchanged. Urinary excretions of sodium and potassium were increased about 1.5 to 2 times as compared to pre-injection control values. Hypotension and natriuresis were followed by increased plasma renin activity in the artery or renal vein. On the other hand, i.v. injection of hydralazine (0.3 mg/kg) promptly decreased DBP and urinary sodium excretion, 15 min after administration, with blood pressure tending to revert to the control value. These results indicate that cadralazine has hypotensive and renal vasodilating actions, characterized by a slow onset and long duration, when compared with hydralazine. Reference: Arzneimittelforschung. 1988 Jan;38(1):25-8. https://pubmed.ncbi.nlm.nih.gov/3284531/

Preparing Stock Solutions

The following data is based on the product molecular weight 283.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

In vitro protocol:

In vivo protocol:

1. Yukimura T, Miura K, Tanaka M, Higashio T, Sakaguchi S, Kuroda K, Yamamoto K. Effects of cadralazine on systemic blood pressure, renal function and plasma renin activity in anesthetized dogs. Arzneimittelforschung. 1988 Jan;38(1):25-8. PMID: 3284531.

1: McTavish D, Young RA, Clissold SP. Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. Drugs. 1990 Oct;40(4):543-60. doi: 10.2165/00003495-199040040-00005. PMID: 2083513. 2: Semeraro C, Dorigotti L, Banfi S, Carpi C. Pharmacological studies on cadralazine: a new antihypertensive vasodilator drug. J Cardiovasc Pharmacol. 1981 May-Jun;3(3):455-67. doi: 10.1097/00005344-198105000-00005. PMID: 6168827. 3: Bonardi G, Rossi E, Pellegatti M. [14C]cadralazine: absorption, distribution and excretion in rat and dog. Eur J Drug Metab Pharmacokinet. 1983;8(1):25-33. doi: 10.1007/BF03189578. PMID: 6861793. 4: Andersson OK. Cadralazine did not produce the SLE-syndrome when hydralazine did. Eur J Clin Pharmacol. 1987;31(6):741. doi: 10.1007/BF00541309. PMID: 3556384. 5: Caponnetto S, Valvo E, Mocarelli P, Alberti D, Savonitto S. Cadralazine versus prazosin as second-step treatment in hypertensive patients on beta- blockers: a randomized multicentre study. The Italian Multicentre Study Group. Eur J Clin Pharmacol. 1991;40(5):461-5. doi: 10.1007/BF00315223. PMID: 1679390. 6: Catalano M, Parini J, Romano M, Libretti A. Controlled clinical trial of cadralazine as a second-step drug in the treatment of hypertension. Eur J Clin Pharmacol. 1985;28(2):135-8. doi: 10.1007/BF00609680. PMID: 3886402. 7: Salvadeo A, Villa G, Segagni S, Piazza V, Picardi L, Romano M, Parini J. Cadralazine, a new vasodilator, in addition to a beta-blocker for long-term treatment of hypertension. Arzneimittelforschung. 1985;35(3):623-5. PMID: 2859865. 8: Dorigotti L, Ferni G, Lombroso M, Semeraro C. Hemodynamic profile of the antihypertensive vasodilator cadralazine in conscious dogs. Arzneimittelforschung. 1984;34(9):984-7. PMID: 6542375. 9: Nishimori T, Nishimura T, Kobayashi F, Nakano D, Fukuda Y, Sakonjyo H, Nakanishi J, Kimura A, Tsuji H, Higashio T, et al. [Effects of cadralazine on the respiration, circulation, kidney, autonomic nervous system, digestive system, blood and so on]. Nihon Yakurigaku Zasshi. 1988 Apr;91(4):221-36. Japanese. doi: 10.1254/fpj.91.221. PMID: 3391446. 10: Leonetti G, Parini J, Visconti M, Gradnik R. Pharmacokinetics of cadralazine in hypertensive patients. Eur J Drug Metab Pharmacokinet. 1988 Oct- Dec;13(4):295-300. doi: 10.1007/BF03190093. PMID: 3243325. 11: Costa FV, Borghi C, Mussi A, Ambrosioni E. Cadralazine and chlorthalidone as a second-step drug with atenolol in hypertensive patients: differences in blood pressure control during exercise. Eur J Clin Pharmacol. 1986;30(2):145-50. doi: 10.1007/BF00614292. PMID: 3709638. 12: Voto LS, Lapidus AM, Catuzzi P, Uranga Imaz F, Zin C, Margulies M. Cadralazine for the treatment of preeclampsia. An open, noncomparative, dose- finding pilot study. Hypertension. 1992 Feb;19(2 Suppl):II132-6. doi: 10.1161/01.hyp.19.2_suppl.ii132. PMID: 1735567. 13: Brunel P, Lecaillon JB, Guyene TT, Imhof P, Ménard J. Influence of acetylator status on the haemodynamic effects and pharmacokinetics of cadralazine in healthy subjects. Br J Clin Pharmacol. 1990 May;29(5):503-9. doi: 10.1111/j.1365-2125.1990.tb03672.x. PMID: 2190629; PMCID: PMC1380148. 14: Schütz H, Faigle JW, Küng W, Theobald W. Disposition and pharmacokinetics of cadralazine and individual metabolites in man. Eur J Drug Metab Pharmacokinet. 1985 Apr-Jun;10(2):147-53. doi: 10.1007/BF03189709. PMID: 4043143. 15: Pålsson L, Weiner L, Englund G, Henning M. Cadralazine challenge in patients with previous hydralazine-induced lupus: a 6-month study. Clin Pharmacol Ther. 1989 Aug;46(2):177-81. doi: 10.1038/clpt.1989.123. PMID: 2758727. 16: Higashio T, Tsuji Y, Nakao K, Sakaguchi S, Tanaka M. Hemodynamic effects of cadralazine in hexamethonium treated and non-treated anesthetized dogs. Arzneimittelforschung. 1988 Mar;38(3):350-8. PMID: 3382459. 17: Nishimori T, Morino K, Tsuchiyama M, Ikeda H, Hasegawa K, Higashio T, Akita S, Yamauchi T, Nakao K, Inukai T. [Effects of cadralazine on the central nervous system]. Nihon Yakurigaku Zasshi. 1988 Apr;91(4):209-20. Japanese. doi: 10.1254/fpj.91.209. PMID: 3391445. 18: Haglund K, Dahlqvist R, Emilsson H, Englund G. Cadralazine pharmacokinetics --a pilot study. Eur J Clin Pharmacol. 1988;35(5):571-2. doi: 10.1007/BF00558256. PMID: 3234466. 19: Persson B, Granerus G, Wysocki M, Hedner T, Andersson OK. Acute systemic and renal haemodynamic effects and long-term antihypertensive action of cadralazine in patients pretreated with beta-blockers and diuretics. Eur J Clin Pharmacol. 1987;31(5):513-8. doi: 10.1007/BF00606622. PMID: 2881788. 20: Marichal JF, Brunel P, Lecaillon JB, Godbillon J, Faller B, Brignon P, Ménard J. Pharmacokinetics of cadralazine and its hydrazino-metabolite in patients with renal impairment after repeated administration of 5 mg once daily. Eur J Drug Metab Pharmacokinet. 1992 Jul-Sep;17(3):213-20. doi: 10.1007/BF03190148. PMID: 1490491.